Modifying PEST for Psoriatic Arthritis Screening
Recruiting now NCT06382051
Run by Novartis Pharmaceuticals · for 18 and older · All sexes · accepts healthy volunteers
What this study is about
The purpose of this study is to assess the impact of adding two questions and pictures to the validated PEST on the potential diagnosis of PsA in participants with moderate-to-severe plaque PsO in Canada.
Who can join (things the study team will check)
✅ You may be able to join if…
- Moderate-to-severe plaque PsO patients who are candidates for bDMARDs, according to physician's clinical judgement at the time of patient enrollment.
- Adult patients at the time of informed consent signature
- Patients able to understand and willing to comply with protocol requirements, instructions, and restrictions
- Residents of Canada
🚫 You may not be able to join if…
- Patients who have previously screened positive for PsA through PEST.
- Patients who have been diagnosed with PsA.
- Patients who have been diagnosed with inflammatory arthritis unrelated to PsA (rheumatoid arthritis, reactive arthritis, enteropathic arthritis, axial spondyloarthritis)
- Patients treated with a bDMARD for moderate-to-severe plaque PsO or any other medical condition within the last 6 months prior to patient enrollment.
Where this trial is running
- Novartis Investigative Site, Calgary, Alberta, Canada
- Novartis Investigative Site, Edmonton, Alberta, Canada
- Novartis Investigative Site, Edmonton, Alberta, Canada
- Novartis Investigative Site, Kelowna, British Columbia, Canada
- Novartis Investigative Site, Surrey, British Columbia, Canada
- Novartis Investigative Site, Winnipeg, Manitoba, Canada
- Novartis Investigative Site, Fredericton, New Brunswick, Canada
- Novartis Investigative Site, Barrie, Ontario, Canada
- Novartis Investigative Site, Greater Sudbury, Ontario, Canada
- Novartis Investigative Site, Hamilton, Ontario, Canada
- Novartis Investigative Site, Hamilton, Ontario, Canada
- Novartis Investigative Site, Hamilton, Ontario, Canada
+ 17 more sites.
Who to contact
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06382051.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.